This is the authors' abstract. We don't add key points for this paper.
A consistent framework for the acceptance and qualification of biomarkers for regulatory use is needed to facilitate innovative and efficient research and subsequent application of biomarkers in drug development. One key activity is biomarker qualification, a graded, "fit-for-purpose" evidentiary process linking a biomarker with biology and clinical end points. A biomarker consortium model will distribute cost and risk, and drive efficient execution of research and ultimately regulatory acceptance of biomarkers for specific indications.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Wagner et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: